A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2018
At a glance
- Drugs ATL 101 Telix Pharmaceuticals (Primary) ; Hydrocortisone; J 591-radiolabelled; Ketoconazole
- Indications Adenocarcinoma; Cancer metastases; Prostate cancer
- Focus Therapeutic Use
- 27 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 27 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated